ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO019

Direct-Acting Oral Antiviral Therapy in the Treatment of Chronic Hepatitis C Is Associated with an Interim Increase in Serum Creatinine Levels

Session Information

Category: Acute Kidney Injury

  • 003 AKI: Clinical and Translational


  • Adiga, Avinash Govinda, Texas Tech University Health Sciences Center, LUBBOCK, Texas, United States
  • Ratanasrimetha, Praveen, Texas Tech University, Lubbock, Texas, United States

The introduction of newer all-oral, direct-acting antiviral therapy in place of traditional interferon-based therapy has revolutionized the management of CHC infection. The aims of our study are to evaluate i) Renal adverse effects related to all oral direct- acting, antiviral therapy for hepatitis C ii) relationship between changes in viral load and renal function tests in chronic hepatitis C patients.


A retrospective study involving 164 patients with chronic hepatitis C infection followed up in outpatient clinics between October 1, 2014, and September 30, 2015. Ninety- five patients who received antiviral therapy were included as cases and sixty-nine patients who did not receive treatment were included as controls. Creatinine levels of cases were noted at four- time points: pre-treatment, at four weeks, at the end of treatment (3 months), and at 12-week post-treatment (6 months) and at the similar time frame for controls. Patients with CKD stage 3 or more and patients with missing values were excluded.


The rate of kidney disease in our study population is 8.7%. Baseline creatinine in the studied population was 0.92mg/dl. Viral clearance was seen in 98.9% of patients, who received the treatment. At the end of treatment, higher creatinine levels were seen in the treatment group than the control group. However, no significant differences in creatinine levels were seen at 6 months. When compared to baseline statistically significant increase in creatinine levels were seen at 3 months and 6 months were seen in both groups.


Serum creatinine levels are higher at the end of treatment in patients receiving anti-viral therapy when compared to controls. This difference tends to cease with further time duration. A decrease in the hepatitis C viral load is not associated with a concurrent decrease in creatinine levels.